{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:00:07Z","timestamp":1789988407917,"version":"4.0.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"\n Background<\/jats:title>\n Adaptive Phase I\/II designs can jointly use toxicity and efficacy information to guide dose allocation and regimen selection. These designs are particularly relevant for oncology drug-combination trials, where the optimal regimen may not coincide with the maximum tolerated dose.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We conducted a structured narrative review of adaptive Phase I\/II designs for oncology drug combinations that use both toxicity and efficacy information for adaptive allocation or final regimen selection. PubMed was searched through April 16, 2026 using terms related to Phase I\/II, seamless design, drug combinations, dose-finding and efficacy, optimal biological dose, dual-agent, efficacy-toxicity trade-off, utility-based dose-finding, and adaptive randomization. Google Scholar and reference lists were used for supplementary citation chasing, and ClinicalTrials.gov was searched for illustrative real-trial applications.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Adaptive Phase I\/II designs for drug combinations were identified across model-based, model-assisted, utility-based, and response-adaptive randomization frameworks for both discrete and continuous dose settings. Across designs, the main trade-offs involved assumptions on monotonicity and ordering, the ability to handle delayed outcomes, transparency of decision rules, computational burden, and software availability. Our targeted search identified few published real-world implementations, and software directly tailored to seamless Phase I\/II combination trials remained limited.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Adaptive Phase I\/II designs for drug combinations are methodologically well developed but remain difficult to implement routinely. Broader use will require clearer design-selection guidance, accessible software, robust delayed-outcome extensions, and protocol templates that communicate operating characteristics to clinical and regulatory stakeholders.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fonc.2026.1916456","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:04:45Z","timestamp":1789985085000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A narrative review of adaptive Phase I\/II clinical trial designs for drug combinations in oncology"],"prefix":"10.3389","volume":"16","author":[{"given":"Junying","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Critical Care and Pain Management, Hospital for Special Surgery","place":["New\u00a0York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Applied Mathematics and Statistics, Stony Brook University","place":["Stony Brook, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Family, Population and Preventive Medicine, School of Medicine, Stony Brook University","place":["Stony Brook, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s1359-6446(04)03023-5","article-title":"The advantages and disadvantages of adaptive designs for clinical trials","volume":"9","author":"Bauer","year":"2004","journal-title":"Drug Discov Today"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1745-6215-13-145","article-title":"Adaptive trial designs: a review of barriers and opportunities","volume":"13","author":"Kairalla","year":"2012","journal-title":"Trials"},{"key":"B3","volume-title":"Adaptive Designs for Clinical Trials of Drugs and Biologics: Guidance for Industry","year":"2019"},{"key":"B4","article-title":"Adaptive clinical trial designs in oncology","volume":"3","author":"Zang","year":"2014","journal-title":"Chin Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2307\/2534012","article-title":"A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I\/II clinical trials","author":"Thall","year":"1998","journal-title":"Biometrics"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-10-1262","article-title":"Seamless phase I-II trial design for assessing toxicity and efficacy for targeted agents","volume":"17","author":"Hoering","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz337","article-title":"DrugComb: an integrative cancer drug combination data portal","volume":"47","author":"Zagidullin","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/82.18.1469","article-title":"Selecting drug combinations based on total equivalent dose (dose intensity)","volume":"82","author":"Simon","year":"1990","journal-title":"JNCI: J Natl Cancer Institute"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2707","article-title":"An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations","volume":"26","author":"Mandrekar","year":"2007","journal-title":"Stat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1541-0420.2006.00534.x","article-title":"Bayesian dose\u2010finding in phase I\/II clinical trials using toxicity and efficacy odds ratios","volume":"62","author":"Yin","year":"2006","journal-title":"Biometrics"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1541-0420.2006.00685.x","article-title":"A parallel phase I\/II clinical trial design for combination therapies","volume":"63","author":"Huang","year":"2007","journal-title":"Biometrics"},{"key":"B12","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1214\/10-aoas433","article-title":"Bayesian phase I\/II adaptively randomized oncology trials with combined drugs","volume":"5","author":"Yuan","year":"2011","journal-title":"Ann Appl Stat"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1002\/sim.6097","article-title":"Phase I\/II adaptive design for drug combination oncology trials","volume":"33","author":"Wages","year":"2014","journal-title":"Stat Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/rssc.12162","article-title":"Parametric dose standardization for optimizing two-agent combinations in a phase I\u2013II trial with ordinal outcomes","volume":"66","author":"Thall","year":"2017","journal-title":"J R Stat Soc Ser C Appl Stat"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/rssc.12293","article-title":"An information theoretic phase I\u2013II design for molecularly targeted agents that does not require an assumption of monotonicity","volume":"68","author":"Mozgunov","year":"2019","journal-title":"J R Stat Soc Ser C Appl Stat"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/bimj.201800313","article-title":"A flexible design for advanced phase I\/II clinical trials with continuous efficacy endpoints","volume":"61","author":"Mozgunov","year":"2019","journal-title":"Biom J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/rssc.12294","article-title":"Two-stage design for phase I\u2013II cancer clinical trials using continuous dose combinations of cytotoxic agents","volume":"68","author":"Tighiouart","year":"2019","journal-title":"J R Stat Soc Ser C Appl Stat"},{"key":"B18","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1111\/rssc.12598","article-title":"Combining cytotoxic agents with continuous dose levels in seamless phase I-II clinical trials","volume":"71","author":"Jim\u00e9nez","year":"2022","journal-title":"J R Stat Soc Ser C Appl Stat"},{"key":"B19","doi-asserted-by":"crossref","first-page":"2200288","DOI":"10.1002\/bimj.202200288","article-title":"A Bayesian adaptive design for dual\u2010agent phase I\u2013II oncology trials integrating efficacy data across stages","author":"Jim\u00e9nez","year":"2023","journal-title":"Biom J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10543406.2023.2236208","article-title":"A Bayesian phase I\u2013II clinical trial design to find the biological optimal dose on drug combination","author":"Wang","year":"2023","journal-title":"J Biopharm Stat"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2307\/2531693","article-title":"Design and analysis of phase I clinical trials","author":"Storer","year":"1989","journal-title":"Biometrics"},{"key":"B22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2307\/2531628","article-title":"Continual reassessment method: a practical design for phase 1 clinical trials in cancer","author":"O'Quigley","year":"1990","journal-title":"Biometrics"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/1740774509105076","article-title":"Model calibration in the continual reassessment method","volume":"6","author":"Lee","year":"2009","journal-title":"Clin Trials"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6961","article-title":"A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials","volume":"36","author":"Tighiouart","year":"2017","journal-title":"Stat Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2015.01.016","article-title":"A phase I\/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma","volume":"41","author":"Wages","year":"2015","journal-title":"Contemp Clin Trials"},{"key":"B26","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/annonc\/mdw681","article-title":"Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapies","volume":"28","author":"Wages","year":"2017","journal-title":"Ann Oncol"},{"key":"B27","unstructured":"CRM: continual reassessment method (CRM) for phase I clinical trials\n \n \n \n Mo\n Q\n \n \n \n 2018"},{"key":"B28","unstructured":"dfcrm: dose-finding by the continual reassessment method\n \n \n \n Cheung\n K\n \n \n \n 2019"},{"key":"B29","unstructured":"crmPack: object-oriented implementation of CRM designs\n \n \n \n Bove\n DS\n \n \n Yeung\n WY\n \n \n Palermo\n G\n \n \n Jaki\n T\n \n \n \n 2022"},{"key":"B30","unstructured":"bcrm: bayesian continual reassessment method for phase I dose-escalation trials\n \n \n \n Sweeting\n M\n \n \n Wheeler\n G\n \n \n \n 2019"},{"key":"B31","unstructured":"trialr: clinical trial designs in \u2019rstan\u2019\n \n \n \n Brock\n K\n \n \n \n 2023"},{"key":"B32","unstructured":"ewoc: escalation with overdose control\n \n \n \n Diniz\n MA\n \n \n \n 2020"},{"key":"B33","unstructured":"BOIN: bayesian optimal INterval (BOIN) design for single-agent and drug-combination phase I clinical trials\n \n \n \n Yuan\n Y\n \n \n Liu\n S\n \n \n \n 2021"},{"key":"B34","unstructured":"pocrm: dose finding in drug combination phase I trials using PO-CRM\n \n \n \n Wages\n NA\n \n \n \n 2021"},{"key":"B35","unstructured":"MinEDfind: A bayesian design for minimum effective dosing- finding trial\n \n \n \n Hsu\n CW\n \n \n Wang\n F\n \n \n Mu\n R\n \n \n Pan\n H\n \n \n Xu\n G\n \n \n \n 2020"},{"key":"B36","unstructured":"clinfun: clinical trial design and data analysis functions\n \n \n \n Seshan\n VE\n \n \n Whiting\n K\n \n \n \n 2023"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0336146","article-title":"crm12comb: Phase I\/II adaptive design for drug combinations based on CRM design through R","volume":"20","author":"Wang","year":"2025","journal-title":"PloS One"},{"key":"B38","unstructured":"dfcomb: phase I\/II adaptive dose-finding design for combination studies\n \n \n \n Riviere\n MK\n \n \n Jourdan\n JH\n \n \n \n 2023"},{"key":"B39","doi-asserted-by":"crossref","DOI":"10.1111\/j.0006-341X.2004.00218.x","article-title":"Dose\u2010finding based on efficacy\u2013toxicity trade\u2010offs","volume":"60","author":"Thall","year":"2004","journal-title":"Biometrics"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/po.20.00257","article-title":"BOIN12: Bayesian optimal interval phase I\/II trial design for utility-based dose finding in immunotherapy and targeted therapies","volume":"4","author":"Lin","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/sim.9337","article-title":"TITE-BOIN12: A Bayesian phase I\/II trial design to find the optimal biological dose with late-onset toxicity and efficacy","volume":"41","author":"Zhou","year":"2022","journal-title":"Stat Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6434","article-title":"A product of independent beta probabilities dose escalation design for dual-agent phase I trials","volume":"34","author":"Mander","year":"2015","journal-title":"Stat Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1916456\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:04:52Z","timestamp":1789985092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1916456\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":42,"alternative-id":["10.3389\/fonc.2026.1916456"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1916456","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"article-number":"1916456"}}